# Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

> **NCT03322995** · PHASE2 · RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 125 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** First-line Chemotherapy
- **DRUG:** Second-line Chemotherapy
- **RADIATION:** Chemoradiation

## Key facts

- **NCT ID:** NCT03322995
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-06-21
- **Primary completion:** 2027-06-01
- **Final completion:** 2032-06-01
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322995, "Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03322995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*